随机对照试验中应用的衰弱指数真的能衡量衰弱吗?
该研究比较了随机对照试验(RCT)与队列研究中累积缺陷衰弱指数所包含的缺陷范围与类型。结果发现,心血管RCT的衰弱指数以心血管代谢缺陷为主,而身体功能指标较少,提示此类指数在用于指导治疗决策前需针对衰弱人群重要结局进行验证。
要点
- RCT衰弱指数的缺陷数量中位数41,队列研究中位数35,数量相似。
- 心血管RCT衰弱指数中心血管代谢缺陷占比中位数47%,远高于队列研究的19%。
- 心血管RCT身体功能指标占比中位数4%,低于其他RCT的16%和队列的17%。
核心结论
- 许多心血管RCT的衰弱指数侧重心血管代谢缺陷而非功能测量,需针对衰弱人群重要结局验证后方可用于指导治疗,在此之前应强调谨慎。
研究设计与样本
- 从近期系统综述中识别使用累积缺陷衰弱指数评估治疗效果修饰的RCT,以及评估衰弱与死亡风险的队列研究,提取并比较各来源衰弱指数所包含的缺陷。
主要发现
- RCT衰弱指数的缺陷数量中位数为41(IQR 35-50),队列研究为35(IQR 31-45),数量相似。
- RCT与队列研究用于识别缺陷的数据来源大致相似。
- 心血管RCT中心血管代谢缺陷占所包含缺陷比例的中位数为47%(IQR 38%-51%),队列研究为19%(IQR 14%-24%)。
- 心血管RCT中身体功能测量占比中位数为4%(IQR 3%-9%),其他疾病RCT为16%(IQR 13%-17%),队列研究为17%(IQR 13%-23%)。
临床怎么用
- 在老年医学科解读RCT衰弱指数时,需注意心血管试验的指数可能偏重心血管代谢缺陷而低估功能损害。
- 使用RCT衰弱指数指导治疗决策前,应确认其已在衰弱人群重要结局中得到验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cumulative deficit frailty indices from randomised controlled trials (RCT) are increasingly used to assess whether trial findings are applicable to people living with frailty. The aim of this paper was to examine the range and type of deficits included in these frailty indices and compare these to those from cohort studies. METHODS: We identified RCTs assessing treatment effect modification using the cumulative deficit frailty index, as well as cohort studies assessing mortality risk associated with frailty, from recent systematic reviews. We extracted the deficits included in the frailty index from each RCT and cohort study. We compared the number of deficits, data sources (e.g. medical history, physical measurements, questionnaires, etc.) and physiological domain (e.g. cardiometabolic, neuro-cognitive, physical function, etc.) of the deficits from each source. RESULTS: The number of deficits was similar between RCT frailty indices (median 41 deficits, interquartile range [IQR] 35-50) and cohort studies (median 35, IQR 31-45). Broadly similar data sources were used to identify deficits. However, in RCTs of cardiovascular conditions, cardiometabolic deficits made up a greater proportion of deficits (median 47% of included deficits, IQR 38%-51%, compared to 19%, 14%-24%, in cohort studies). Cardiovascular RCTs included fewer physical function measures (median 4% [3%-9%], compared to 16% in other RCTs of other conditions [13%-17%], 17% in cohort [13%-23%]). CONCLUSION: In many cardiovascular RCTs, frailty indices focus on cardiometabolic deficits rather than measures of function. These frailty indices need to be validated against outcomes important to people living with frailty before being used to inform treatment. Until then, we would emphasise caution.
引用
- Bousetta R, McAllister DA, Wightman H, et al. Does the frailty index applied to randomised controlled trials really measure frailty? Age Ageing. 2025. PMID: 41134536. doi:10.1093/ageing/afaf314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。